In Re Silicone Implant Insurance Coverage Litigation

667 N.W.2d 405, 2003 Minn. LEXIS 511
CourtSupreme Court of Minnesota
DecidedAugust 21, 2003
DocketC5-01-1546, C3-01-1738, C3-01-1741, C5-01-1742, C4-01-1747, C6-01-1748, C4-01-1778, C9-01-1811, C0-01-1812, C1-01-1821, C4-01-1828, C6-01-1829, C8-01-1850, C2-01-1861, C4-01-1862, C7-01-1869, C6-01-1894, CX-01-1896, C1-01-1897, C9-01-1906; C3-01-1917, C3-01-1920, C7-01-1922, C2-01-1925, C3-01-1965
StatusPublished
Cited by47 cases

This text of 667 N.W.2d 405 (In Re Silicone Implant Insurance Coverage Litigation) is published on Counsel Stack Legal Research, covering Supreme Court of Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Silicone Implant Insurance Coverage Litigation, 667 N.W.2d 405, 2003 Minn. LEXIS 511 (Mich. 2003).

Opinion

OPINION

ANDERSON, PAUL H, Justice.

This appeal stems from a declaratory judgment action brought by several of 3M’s high-level, excess-layer, occurrence-based policy insurers. These insurers sought to clarify their coverage obligations in 3M’s ongoing silicone gel breast implant mass tort litigation. The insurance policies at issue were in place from 1977 to 1985 and covered claims arising from injuries occurring during that time period. The implant claims for which 3M sought *409 reimbursement were brought in the early 1990s, but were based largely on implanta-tions that occurred during the policy periods, which implants allegedly caused various systemic autoimmune diseases. The Ramsey County District Court determined that the actual-injury trigger, for purposes of determining coverage liability, began at or around the time of implantation when silicone first leaked and came in contact with body tissue stimulating the immune system. The court found that the injury continued after implantation. The court then determined that 3M’s losses should be allocated pro rata by time on the risk for the period from implantation through December 31, 1985, the end of the time period during which the policies were in place. The court also concluded that the insurers had breached their implied covenant of good faith and fair dealing and that 3M was entitled to reasonable attorney fees and costs as a result.

The court of appeals affirmed the district court’s determinations that the alleged systemic autoimmune diseases constituted a continuing injury and that allocation was appropriate. The court, however, extended the end of the allocation period to the earlier date of the underlying plaintiffs claim or death. The court also reversed the award of attorney fees and costs, concluding that such a remedy is unavailable for this claim. Both sides to this dispute petitioned for and were granted review on the following issues: when and how policy coverage was triggered; whether allocation is appropriate and, if so, when the allocation period should end; whether the insurers are entitled to a judgment reduction; and whether attorney fees and costs are appropriate in this case. We affirm in part and reverse in part.

Between 1977 and 1985, 3M purchased significant amounts of occurrence-based insurance for product liability exposure. 3M purchased primary policies and ascending layers of excess coverage. The petitioner-insurers each provided high-level excess policy coverage, which means that their payment obligations arise only after judgments or settlements have exhausted the substantial primary and lower-level excess policies. Under these occurrence-based policies, coverage is determined by when the alleged bodily injury or property damage took place: all sums related to any such injury or damage that occurred during the policy period are covered by the policy, even if the claim is not asserted until after the end of the policy period.

In 1985, many manufacturers were forced to buy excess coverage in a new form — claims-made policies — which coverage is triggered by the date of the claim instead of the date the injury or damage occurred. These claims-made policies became the new form of excess coverage because product liability insurers no longer offered significant occurrence-based coverage. The claims-made policies were adopted primarily so that insurers could avoid the uncertainty often involved in occurrence-based policies under which insurers may not know the source or totality of their risks at the end of the policy period because claims can be made after expiration of the policy. Under a claims-made policy, insurers do not cover claims submitted after the end of the policy period, even if the injury underlying the claim arose during the policy period. The claims-made policies include a retroactive date that defines the earliest date the injury can have occurred in order for the policy to cover the resulting claim. The most significant difference between occurrence-based and claims-made policies is that occurrence-based policies can be triggered after the expiration of the policy *410 period, while claims-made policies cannot. At the expiration of a claims-made policy, coverage available under the policy disappears.

3M’s switch from occurrence-based to claims-made policies was designed to provide seamless coverage: the claims-made policies had retroactive dates that provided coverage immediately upon the expiration of the occurrence-based policies. Here, the district court found that there was no time during the relevant period that 3M was self-insured, uninsured, or, based on its claim history, underinsured. It found that 3M “sought to transfer its product liability risks to the maximum extent reasonably possible.”

In 1992, 3M began to be named in thousands of complaints alleging that 3M’s silicone gel breast implants caused various symptoms characteristic of a systemic autoimmune disease. The claims arose from injuries allegedly caused by breast implants manufactured by 3M between 1977 and 1984 1 and implanted between 1977 and 1985. 3M notified its claims-made insurers of the breast implant litigation in April 1992. In July 1993, 3M sent notice of the litigation to its occurrence-based policy insurers for the 1977-1985 period. Though 3M defended the claims on the ground that the underlying tort plaintiffs were unable to prove that the implants caused any of the alleged injuries, it eventually settled a class action suit. The petitioner-insurers have stipulated to the reasonableness of the 1995 settlement. While the class action was settled, 3M has continued to defend against and settle claims with the plaintiffs who opted out of the class settlement.

On September 22, 1994, three of 3M’s occurrence-based excess policy insurers commenced this declaratory judgment aetion against 3M and joined most of 3M’s claims-made insurers and other occurrence-based excess insurers to clarify coverage issues raised in the breast implant litigation. The joined occurrence-based excess policy insurers aligned themselves with the other three occurrence-based insurers and became the petitioner-insurers. These petitioner-insurers first sought a declaration that they had no duty to defend, but eventually sought a resolution of the trigger and allocation issues and resolution of the exhaustion requirement. 3M counterclaimed on the declaratory issues, brought claims against the petitioner-insurers alleging breach of contract and breach of the implied covenant of good faith and fair dealing, and asserted statutory and tort claims that were dismissed on motion.

Two of the claims-made insurers that the petitioner-insurers joined in the action, XL Capital Ltd. (XL) and A.C.E. Insurance Co., Ltd. (A.C.E.), moved for their dismissal based on an undertaking 3M had agreed to make in its claims-made policies with these insurers. The undertaking asserted that 3M would agree to a reduction in any judgment against petitioner-insurers if the court determined that XL and A.C.E. shared any common liability with petitioner-insurers. The undertaking thereby protected petitioner-insurers from having to pay losses properly allocated to XL and A.C.E. Agreeing that the undertaking rendered the petitioner-insurers’ claims against XL and A.C.E. moot, the district court dismissed XL and A.C.E. from the action in June 1995.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Radiator Specialty Co. v. Arrowood Indem. Co.
Supreme Court of North Carolina, 2022
National Indemnity v. State
2021 MT 300 (Montana Supreme Court, 2021)
Catlin Specialty Ins. Co. v. J.J. White, Inc.
387 F. Supp. 3d 583 (E.D. Pennsylvania, 2019)
Deere & Co. v. Allstate Ins. Co.
California Court of Appeal, 2019
Deere & Co. v. Allstate Ins. Co.
244 Cal. Rptr. 3d 100 (California Court of Appeals, 5th District, 2019)
Dustin Ray George Dittmar v. George Andrew Karels
Court of Appeals of Minnesota, 2016
CH Properties, Inc. v. First American Title Insurance Co.
214 F. Supp. 3d 111 (D. Puerto Rico, 2016)
Susanna D. Smith v. Wells Concrete Products Co.
Court of Appeals of Minnesota, 2015
Bergen v. Grinnell Mutual Reinsurance Co.
946 F. Supp. 2d 867 (D. Minnesota, 2013)
Unitedhealth Group Inc. v. Columbia Casualty Co.
941 F. Supp. 2d 1029 (D. Minnesota, 2013)
Continental Casualty Co. v. National Union Fire Insurance
940 F. Supp. 2d 898 (D. Minnesota, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
667 N.W.2d 405, 2003 Minn. LEXIS 511, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-silicone-implant-insurance-coverage-litigation-minn-2003.